Display Settings:

Format
Items per page

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 1 to 20 of 32

1.

A change in the way a drug acts in the body when taken with certain other drugs, herbals, or foods, or when taken with certain medical conditions. Drug interactions may cause the drug to be more or less effective, or cause effects on the body that are not expected. [from NCI]

MedGen UID:
146913
Concept ID:
C0687133
2.

Rheumatism

A group of disorders marked by inflammation or pain in the connective tissue structures of the body. These structures include bone, cartilage, and fat. [from NCI]

MedGen UID:
48447
Concept ID:
C0035435
Disease or Syndrome
3.

Methylation

A chemical reaction in which a small molecule called a methyl group is added to other molecules. Methylation of proteins or nucleic acids may affect how they act in the body. [from NCI]

MedGen UID:
44400
Concept ID:
C0025723
Molecular Function
4.

Thioguanine

thioguanine is USP. [from CRISP]

MedGen UID:
21146
Concept ID:
C0039902
Pharmacologic Substance
5.

Azathioprine

an immunosuppressive drug [from CHV]

MedGen UID:
13991
Concept ID:
C0004482
Pharmacologic Substance
6.

Inosine

A purine nucleoside that has hypoxanthine linked by the N9 nitrogen to the C1 carbon of ribose. It is an intermediate in the degradation of purines and purine nucleosides to uric acid and in pathways of purine salvage. It also occurs in the anticodon of certain transfer RNA molecules. (Dorland, 28th ed) [from MeSH]

MedGen UID:
9477
Concept ID:
C0021528
Pharmacologic Substance
7.

Mercaptopurine

An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [from MeSH]

MedGen UID:
7793
Concept ID:
C0000618
Pharmacologic Substance
8.

Inflammation of the large intestine

MedGen UID:
505065
Concept ID:
CN001842
Finding
9.

Error occurred: cannot get document summary

ID:
472459

10.

Error occurred: cannot get document summary

ID:
468932

11.

Mercaptopurine response

Mercaptopurine is an immunosuppressant and antineoplastic agent that belongs to the drug class thiopurines. It is used in combination with other drugs for the maintenance therapy of acute lymphatic leukemia. Thiopurine S-methyltransferase (TPMT) is involved in the metabolism of all thiopurines and is one of the main enzymes that inactivates mercaptopurine. In all patients receiving mercaptopurine, there is a risk of bone marrow suppression. This adverse effect is dose-dependent and may be reversed by reducing the dose of mercaptopurine. However, individuals who inherit two nonfunctional TPMT alleles universally experience life-threatening myelosuppression. The FDA advises that TPMT genotyping or phenotyping can identify individuals who are homozygous for nonfunctional TPMT alleles or have low or intermediate TPMT activity. The Clinical Pharmacokinetics Implementation Consortium (CPIC) has made recommendations on the dosing of mercaptopurine based on an individual's TMPT phenotype. [from Medical Genetics Summaries]

MedGen UID:
450467
Concept ID:
CN077995
Sign or Symptom
12.

Thioguanine

MedGen UID:
450038
Concept ID:
CN077563
Pharmacologic Substance
13.

Life Threatening

A situation that imperils the existence of an entity. [from NCI]

MedGen UID:
415288
Concept ID:
C2826244
Finding
14.

Myelosuppression

A condition in which bone marrow activity is decreased, resulting in fewer red blood cells, white blood cells, and platelets. Myelosuppression is a side effect of some cancer treatments. When myelosuppression is severe, it is called myeloablation. [from NCI]

MedGen UID:
163134
Concept ID:
C0854467
Disease or Syndrome
15.

Thiopurine methyltransferase deficiency

TPMT deficiency is an autosomal recessive trait associated with severe hematopoietic toxicity when patients are treated with standard doses of the antineoplastic agents 6-mercaptopurine (6MP) or 6-thioguanine (6TG), or the immunosuppressant azathioprine (AZA) (Lennard et al., 1989). The thiopurines are pro-drugs that require extensive metabolism in order to exert their cytotoxic action. Azathioprine is non-enzymatically reduced to 6MP. 6MP and 6TG are activated by HPRT (308000) and subsequent steps to form cytotoxic thioguanine nucleotides (TGNs) which are incorporated into DNA and/or RNA, causing DNA-protein cross-links, single-strand breaks, interstrand cross-links, and sister chromatid exchange. TPMT functions mainly to inactivate these drugs; thus, a deficiency of TPMT results in increased conversion to toxic TGNs, which can result in myelosuppression (Coulthard and Hogarth, 2005). However, 6MP is unique in that it can also be converted via TPMT into a methyl-thioinosine 5-prime monophosphate (MeTIMP), a metabolite that inhibits de novo purine synthesis and likely contributes to the cytotoxic effect of 6MP (Vogt et al., 1993; Krynetski et al., 1995; Coulthard and Hogarth, 2005). [from OMIM]

MedGen UID:
83352
Concept ID:
C0342801
Disease or Syndrome
16.

Inflammatory bowel disease

A spectrum of small and large bowel inflammatory diseases of unknown etiology. It includes Crohn's disease, ulcerative colitis, and colitis of indeterminate type. [from NCI]

MedGen UID:
43877
Concept ID:
C0021390
Disease or Syndrome
17.

Tabloid

MedGen UID:
385233
Concept ID:
C2350041
Pharmacologic Substance
18.

A drug used to treat acute lymphatic leukemia. It belongs to the family of drugs called antimetabolites. [from NCI]

MedGen UID:
196307
Concept ID:
C0722911
19.

MedGen UID:
182436
Concept ID:
C0917847
20.

MedGen UID:
149060
Concept ID:
C0729100

Display Settings:

Format
Items per page

Send to:

Choose Destination

Supplemental Content

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...